Literature DB >> 25447299

Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures.

Paul Chu Sin Chung1, Annie Boehrer1, Aline Stephan1, Audrey Matifas1, Grégory Scherrer2, Emmanuel Darcq3, Katia Befort1, Brigitte L Kieffer4.   

Abstract

The delta opioid receptor (DOR) has raised much interest for the development of new therapeutic drugs, particularly to treat patients suffering from mood disorders and chronic pain. Unfortunately, the prototypal DOR agonist SNC80 induces mild epileptic seizures in rodents. Although recently developed agonists do not seem to show convulsant properties, mechanisms and neuronal circuits that support DOR-mediated epileptic seizures remain to be clarified. DORs are expressed throughout the nervous system. In this study we tested the hypothesis that SNC80-evoked seizures stem from DOR activity at the level of forebrain GABAergic transmission, whose inhibition is known to facilitate the development of epileptic seizures. We generated a conditional DOR knockout mouse line, targeting the receptor gene specifically in GABAergic neurons of the forebrain (Dlx-DOR). We measured effects of SNC80 (4.5, 9, 13.5 and 32 mg/kg), ARM390 (10, 30 and 60 mg/kg) or ADL5859 (30, 100 and 300 mg/kg) administration on electroencephalograms (EEGs) recorded in Dlx-DOR mice and their control littermates (Ctrl mice). SNC80 produced dose-dependent seizure events in Ctrl mice, but these effects were not detected in Dlx-DOR mice. As expected, ARM390 and ADL5859 did not trigger any detectable change in mice from both genotypes. These results demonstrate for the first time that SNC80-induced DOR activation induces epileptic seizures via direct inhibition of GABAergic forebrain neurons, and supports the notion of differential activities between first and second-generation DOR agonists.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biased agonism; Conditional knockout; Delta agonist; Delta opioid receptor; Epileptic seizure; In vivo

Mesh:

Substances:

Year:  2014        PMID: 25447299      PMCID: PMC4382405          DOI: 10.1016/j.bbr.2014.10.029

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  24 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 2.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

3.  Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys.

Authors:  Ingela Danielsson; Maciej Gasior; Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

Review 4.  Anxiety and depression: mouse genetics and pharmacological approaches to the role of GABA(A) receptor subtypes.

Authors:  Kiersten S Smith; Uwe Rudolph
Journal:  Neuropharmacology       Date:  2011-07-27       Impact factor: 5.250

Review 5.  The delta opioid receptor: an evolving target for the treatment of brain disorders.

Authors:  Amynah A Pradhan; Katia Befort; Chihiro Nozaki; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  Trends Pharmacol Sci       Date:  2011-09-17       Impact factor: 14.819

6.  Comparison of receptor mechanisms and efficacy requirements for delta-agonist-induced convulsive activity and antinociception in mice.

Authors:  Daniel C Broom; Joshua F Nitsche; John E Pintar; Kenner C Rice; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

7.  Pentylenetetrazole-induced inhibition of recombinant gamma-aminobutyric acid type A (GABA(A)) receptors: mechanism and site of action.

Authors:  R Q Huang; C L Bell-Horner; M I Dibas; D F Covey; J A Drewe; G H Dillon
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

8.  Distribution of delta opioid receptor-expressing neurons in the mouse hippocampus.

Authors:  E Erbs; L Faget; G Scherrer; P Kessler; D Hentsch; J-L Vonesch; A Matifas; B L Kieffer; D Massotte
Journal:  Neuroscience       Date:  2012-06-28       Impact factor: 3.590

Review 9.  Biological studies of post-traumatic stress disorder.

Authors:  Roger K Pitman; Ann M Rasmusson; Karestan C Koenen; Lisa M Shin; Scott P Orr; Mark W Gilbertson; Mohammed R Milad; Israel Liberzon
Journal:  Nat Rev Neurosci       Date:  2012-10-10       Impact factor: 34.870

Review 10.  Delta opioid receptors in brain function and diseases.

Authors:  Paul Chu Sin Chung; Brigitte L Kieffer
Journal:  Pharmacol Ther       Date:  2013-06-10       Impact factor: 12.310

View more
  26 in total

1.  Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

Authors:  Neil T Burford; Kathryn E Livingston; Meritxell Canals; Molly R Ryan; Lauren M L Budenholzer; Ying Han; Yi Shang; John J Herbst; Jonathan O'Connell; Martyn Banks; Litao Zhang; Marta Filizola; Daniel L Bassoni; Tom S Wehrman; Arthur Christopoulos; John R Traynor; Samuel W Gerritz; Andrew Alt
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

2.  The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist.

Authors:  M Alexander Stanczyk; Kathryn E Livingston; Louise Chang; Zara Y Weinberg; Manojkumar A Puthenveedu; John R Traynor
Journal:  Br J Pharmacol       Date:  2019-04-14       Impact factor: 8.739

3.  Delta-opioid receptor-mediated modulation of excitability of individual hippocampal neurons: mechanisms involved.

Authors:  Lucia Moravcikova; Roman Moravcik; Daniela Jezova; Lubica Lacinova; Eliyahu Dremencov
Journal:  Pharmacol Rep       Date:  2020-11-08       Impact factor: 3.024

4.  Targeting Cannabinoid 1 and Delta Opioid Receptor Heteromers Alleviates Chemotherapy-Induced Neuropathic Pain.

Authors:  Salvador Sierra; Achla Gupta; Ivone Gomes; Mary Fowkes; Akila Ram; Erin N Bobeck; Lakshmi A Devi
Journal:  ACS Pharmacol Transl Sci       Date:  2019-06-05

5.  Role of signalling molecules in behaviours mediated by the δ opioid receptor agonist SNC80.

Authors:  Isaac J Dripps; Brett T Boyer; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Br J Pharmacol       Date:  2018-02-09       Impact factor: 8.739

Review 6.  Alleviating pain with delta opioid receptor agonists: evidence from experimental models.

Authors:  Sophie Berthiaume; Khaled Abdallah; Véronique Blais; Louis Gendron
Journal:  J Neural Transm (Vienna)       Date:  2020-03-18       Impact factor: 3.575

Review 7.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

8.  The role of regulator of G protein signaling 4 in delta-opioid receptor-mediated behaviors.

Authors:  Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz
Journal:  Psychopharmacology (Berl)       Date:  2016-09-13       Impact factor: 4.530

9.  Truncated mu opioid GPCR variant involvement in opioid-dependent and opioid-independent pain modulatory systems within the CNS.

Authors:  Gina F Marrone; Steven G Grinnell; Zhigang Lu; Grace C Rossi; Valerie Le Rouzic; Jin Xu; Susruta Majumdar; Ying-Xian Pan; Gavril W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

Review 10.  The delta opioid receptor tool box.

Authors:  Ana Vicente-Sanchez; Laura Segura; Amynah A Pradhan
Journal:  Neuroscience       Date:  2016-06-24       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.